Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK/PD, and Food Effect of CKD-510 in Healthy Volunteers
NCT04746287Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CKD-510 in Charcot-Marie-Tooth disease (CMT) (4 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Number of subjects with adverse events (AEs) up to 4 days, Safety as assessed by vital signs up to 4 days and 3 more. Started Jan 2020; status: completed.
02
Drugs
CKD-510
03
Conditions
Charcot-Marie-Tooth disease (CMT)
Beyond the preview
Go deeper on NCT04746287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746287.